Why is Marksans Pharma falling/rising?

As of 15-Sep, Marksans Pharma Ltd's stock is currently priced at 174.25, reflecting an increase of 1.25 or 0.72%. The stock has shown a positive movement today, gaining after two consecutive days of decline, and has outperformed its sector by 1.17%. In the past week, the stock has risen by 2.95%, although it has underperformed over the last month with a decline of 2.27%. Despite a significant year-to-date drop of 41.18%, the company maintains a high management efficiency with a return on equity (ROE) of 17.66% and a low debt-to-equity ratio, which could support its valuation. However, the stock's performance is tempered by a poor long-term growth outlook, as indicated by a negative annual operating profit growth rate and recent disappointing quarterly results.
In the broader market context, the stock's short-term performance has outpaced the Sensex, which has increased by 1.24% over the same week. However, the stock's year-to-date performance remains significantly worse than the benchmark, which has gained 4.67%. The falling investor participation, as evidenced by a 46.27% drop in delivery volume compared to the five-day average, raises concerns about liquidity and market interest. While high institutional holdings at 25.38% may provide some stability, the overall negative sentiment surrounding the stock's long-term growth prospects and recent financial results continues to weigh heavily on its performance.